EGFR and nasopharyngeal carcinoma: Clinical trials have shown that EGFR-targeted therapy (CTX and NTZ) based on palliative chemotherapy for recurrent or metastatic NPC (R/M NPC) patients significantly increase the chance of progression-free survival (PFS).